Search Results - "Machtens, S."

CXCR4/CXCL12 expression and signalling in kidney cancer by SCHRADER, A. J, LECHNER, O, ATZPODIEN, J, BUER, J, LAUBER, J, TEMPLIN, M, DITTMAR, K. E. J, MACHTENS, S, MENGEL, M, PROBST-KEPPER, M, FRANZKE, A, WOLLENSAK, T, GATZLAFF, P

“…CXCL12 (SDF-1), a CXC-chemokine, and its specific receptor, CXCR4, have recently been shown to be involved in tumourgenesis, proliferation and angiogenesis…”
Get full text

Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage by Wendler, J. J., Ganzer, R., Hadaschik, B., Blana, A., Henkel, T., Köhrmann, K. U., Machtens, S., Roosen, A., Salomon, G., Sentker, L., Witzsch, U., Schlemmer, H. P., Baumunk, D., Köllermann, J., Schostak, M., Liehr, U. B.

“…Irreversible electroporation (IRE), a new tissue ablation procedure available since 2007, could meet the requirements for ideal focal therapy of prostate…”
Get full text

SP-0348: Long-term results of LDR seed monotherapy in the treatment of prostate cancer by Machtens, S.

Get full text

SU‐FF‐T‐280: LDR Brachytherapy for Low Risk Prostate Cancer with I‐125 — a Comparison of the Results with Loose Seeds From Two Different Producers by Baumann, R, Machtens, S, Warszawski, A

“…Purpose: LDR brachytherapy is a well established treatment method for low risk prostate cancer. Different techniques and radioactive sources are used. In this…”
Get full text

Partial Volume Analysis Predicting Late Side Effects in LDR Brachytherapy of Prostate Cancer by Baumann, R, Warszawski, A, Wassermann, J, Machtens, S, Karstens, J

Get full text

Cancer control in focus insights and future perspectives for the focal treatment of prostate cancer by Schostak, M, Köllermann, J, Hadaschik, B, Blana, A, Ganzer, R, Henkel, T, Köhrmann, K U, Liehr, U-B, Machtens, S, Roosen, A, Salomon, G, Sentker, L, Witzsch, U, Schlemmer, H-P, Baumunk, D

“…Faced with the dilemma of choosing between the extremes of standard whole gland therapy and active surveillance, those affected by prostate cancer have…”
Get more information

SU‐FF‐T‐335: Partial Volume Analysis in LDR Brachytherapy of Prostate Cancer — Comparison of Intraoperative Ultrasound Planning and Post Implant CT Dosimetry by Baumann, R, Wassermann, J, Machtens, S, Karstens, J, Warszawski, A

“…Purpose: Dose distribution in the base and apex of prostate and in the penile bulb in permanent seed implantations may influence the probability of urinary…”
Get full text

The need for routine adrenalectomy during surgical treatment for renal cell cancer: the Hannover experience by Kuczyk, M., Münch, T., Machtens, S., Bokemeyer, C., Wefer, A., Hartmann, J., Kollmannsberger, C., Kondo, M., Jonas, U.

“…Objectives To further clarify the need for routine adrenalectomy during the surgical treatment of renal cell cancer, as in the absence of clinically overt…”
Get full text

Testosterone therapy in the ageing male: what about the prostate? by SCHULTHEISS, D, MACHTENS, S, JONAS, U

“…The concerns about testosterone therapy in ageing men with late-onset hypogonadism mainly address the risk of prostatic disease, i.e. either benign prostatic…”
Get full text

TGF-beta1 Gene Polymorphism and Quality of Life in Prostate Cancer Patients Treated with Brachytherapy Seed Implantation by Meyer, A, Dörk, T, Bogdanova, N, Brinkhaus, M, Wiese, B, Bremer, M, Baumann, R, Karstens, J.H, Machtens, S

Get full text

SU‐FF‐T‐45: Partial Volume Analysis in Permanent Seed Implantations by Baumann, R, Warszawski, A, Machtens, S, Karstens, J

“…Purpose: Permanent seed implantation is a well accepted therapy for the treatment of low risk prostate cancer. In Europe the number of treated patients…”
Get full text

Tissue microarrays : applications in urological cancer research by MERSEBURGER, A. S, ANASTASIADIS, A. G, HENNENLOTTER, J, SCHILLING, D, SIMON, P, MACHTENS, S. A, SERTH, J, STENZL, A, KUCZYK, M. A

“…Tissue microarrays (TMAs) are used to simultaneously study the expression of proteins in hundreds of tissue samples, offering the important advantage to screen…”
Get full text

Positron emission tomography (PET) in the urooncological evaluation of the small pelvis by Machtens, S, Serth, J, Meyer, A, Kleinhorst, C, Ommer, K-J, Herbst, U, Kieruij, M, Boerner, A R

“…Positron emission tomography (PET) with the use of ((18)F)2-fluoro-D: -2-desoxyglucose (FDG) has been investigated to be a highly sensitive and specific…”
Get full text

Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia by Höfner, K, Oelke, M, Machtens, S, Grünewald, V

“…Trospium chloride (TCL), a quaternary ammonium derivative of nortropanol, has been evaluated in a number of clinical and pharmacological studies. Selected…”
Get full text

Changes in the treatment of metastatic prostate cancer-new data and open questions by Albers, P, Bögemann, M, Machtens, S, Merseburger, A S, Schostak, M, Steuber, T, Wülfing, C, De Santis, M

“…The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients…”
Get full text

Predictive value of decreased p27 protein expression for the recurrence-free and long-term survival of prostate cancer patients

Get full text

Erectile dysfunction in relation to traumatic pelvic injuries or pelvic fractures by Machtens, S., Gänsslen, A., Pohlemann, T., Stief, C.G.

Get full text

POD-05.06: The peripheral role of serotonin reuptake inhibitors on the human seminal vesicle: in vitro study by Birowo, P, Ückert, S, Kedia, G, Keil, C, Meyer, M, Mägert, H.J, Machtens, S, Thon, W.F, Scheller, F, Jonas, U, Taher, A, Rahardjo, D

Get full text

P233 - Patient and physician preferences for treatments of metastatic castrate resistant prostate cancer by Castro, E., Jones, R., Machtens, S., Uemura, H., Mclaurin, K., Yeh, N., Payne, S., Cain, T., Collacott, H., Gabriela, F., Heidenreich, S., Morgans, A.

Get full text

Patient and physician preferences for treatments of metastatic castrate resistant prostate cancer by Castro, E., Jones, R., Machtens, S., Uemura, H., Mclaurin, K., Yeh, N., Payne, S., Cain, T., Collacott, H., Gabriela, F., Heidenreich, S., Morgans, A.

Get full text